

### REMARKS

Claims 53 and 55-58 are allowed in this application. The Examiner indicated in the Office Communication dated that October 11, 2005 that Applicant is required to provide any previous amendments presented during the Interference proceeding to complete the instant file application.

The Amendment filed in connection with the above-identified application was withdrawn. However, to clarify the presently pending claims, claim 53 has been amended. Support for the amendments to claim 53 can be found in the specification. Support for the recitation that the 8F4 polypeptide occurs on two-signal-activated human "CD4<sup>+</sup> T lymphocytes from human peripheral blood" can be found, *e.g.*, on page 12, line 20 and page 12, line 1 of the specification. Claim 53 has also been amended to clarify that the 8F4 polypeptide is recognized by the antibody "produced by the hybridoma" deposited with the DSMZ and assigned accession no. DSM ACC2539, since the hybridoma, not the antibody itself, was the subject matter of the DSMZ deposit (see Statement of Applicant Regarding Permanence and Availability of Deposited Microorganisms submitted in connection with the related application no. 09/823,307 on October 15, 2002).

No new matter is added.

**CONCLUSION**

Applicant respectfully requests that the amendment and remarks made herein be entered and made of record in the file history of the subject application.

Respectfully submitted,

Date: November 23, 2005

Nikolaos C. George 39,201  
Nikolaos C. George (Reg. No.)

**JONES DAY**

222 E. 41<sup>st</sup> Street

New York, New York 10017

(212) 326-3939

by: Muna Abu Shan  
Limited Recognition (L0012)